The biopharmaceutical company focuses on T-cell receptor (TCR) engineered T cell therapies (TCR-T) for cancer treatment, with lead liquid tumor TCR-T therapy candidates TSC-100 and TSC-101 in development for hematologic malignancies. TScan is also developing multiplexed TCR-T therapy candidates for various solid tumors. Founded in 2018 by a group of scientists led by Dr. Stephen Elledge, TScan's discovery platform uses breakthrough technology to rapidly identify peptide antigen targets of T cell receptors, enhancing their ability to understand specific antigens that drive important disease processes and move novel TCRs into clinical development.